| Budget Amount *help |
¥18,460,000 (Direct Cost: ¥14,200,000、Indirect Cost: ¥4,260,000)
Fiscal Year 2014: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥9,750,000 (Direct Cost: ¥7,500,000、Indirect Cost: ¥2,250,000)
|
|---|
| Outline of Final Research Achievements |
Oncolytic virotherapy is based on the ability of virus to destroy tumor cells. We investigated whether the oncolytic herpes simplex virus type 1 (HSV-1) RH2 exerted an enhancing effect on tumor immunity for squamous cell carcinoma. In a bilateral tumor model with synergistic mice, tumors in one side were injected with RH2 and other side tumors left untreated. The growth of tumors of RH2-treated animals was reduced in both sides than that in untreated mice, indicating the enhancement of tumor immunity by RH2. In RH2-infected SCC cells, damage-associated molecular patterns (DAMPs) were produced. Proteome analysis revealed the presence of DAPMs in the supernatants of RH2-infected cells. These results indicate that RH2 stimulates tumor immunity through the function to produce immunogenic proteins including DAMPs.
|
